“Is there something that Pharma can learn from Apple Inc. and the High Tech industry?”
Will the classic, opportunistic BD&L approach suffice to satisfy licensing and partnering demands in the 21st century?
Are you open to innovation?
“How can billions of risk-adjusted pipeline value disappear overnight?”
My decision to join Catenion? Here I found what I was looking for – high level strategy work, international clients and the team spirit of a smaller firm.
“How can our clients develop an effective strategy which accounts for the rapidly changing drug reimbursement landscape?”